Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.

Apperloo EM, Tuttle KR, Pavo I, Haupt A, Taylor R, Wiese RJ, Hemmingway A, Cherney DZI, Sattar N, Heerspink HJL

Diabetes care1 Mar 2025Cited by 44 (Europe PMC)

PMID39746157PMCIDPMC11870291DOI10.2337/dc24-1773PepBankPUB-39746157

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg lowered urine albumin-to-creatinine ratio by 19.3% versus pooled comparators at week 40/42.
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg lowered a urine marker of kidney damage compared with other treatments pooled.
Peptide
Tirzepatide
Outcome
DecreasePercent change in UACR, tirzepatide 5 mg
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
5 mg · week 40/42As given in this study (human).
Measurements
UACR percent change
−19.3%
tirzepatide 5 mg
Source sentences
Summary
The adjusted mean percent change from baseline in UACR for tirzepatide 5, 10, or 15 mg compared with all pooled comparators was -19.3% (95% CI -25.5, -12.5)
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg lowered urine albumin-to-creatinine ratio by 22.0% versus pooled comparators at week 40/42.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg lowered a urine marker of kidney damage compared with other treatments pooled.
Peptide
Tirzepatide
Outcome
DecreasePercent change in UACR, tirzepatide 10 mg
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
10 mg · week 40/42As given in this study (human).
Measurements
UACR percent change
−22%
tirzepatide 10 mg
Source sentences
Summary
The adjusted mean percent change from baseline in UACR for tirzepatide 5, 10, or 15 mg compared with all pooled comparators was -19.3% (95% CI -25.5, -12.5), -22.0% (-28.1, -15.3), and -26.3 (-32.0, -20.0), respectively, at week 40/42.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg lowered urine albumin-to-creatinine ratio by 26.3% versus pooled comparators at week 40/42.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered a urine marker of kidney damage compared with other treatments pooled.
Peptide
Tirzepatide
Outcome
DecreasePercent change in UACR, tirzepatide 15 mg
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
15 mg · week 40/42As given in this study (human).
Measurements
UACR percent change
−26.3%
tirzepatide 15 mg
Source sentences
Summary
The adjusted mean percent change from baseline in UACR for tirzepatide 5, 10, or 15 mg compared with all pooled comparators was -19.3% (95% CI -25.5, -12.5), -22.0% (-28.1, -15.3), and -26.3 (-32.0, -20.0), respectively, at week 40/42.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, UACR results for tirzepatide were similar across pooled placebo, active and insulin comparator studies.
In plain wordsIn adults with type 2 diabetes, tirzepatide lowered the urine kidney marker in a similar way against placebo, active drugs and insulin.
Peptide
Tirzepatide
Outcome
DecreaseUACR reduction across placebo, active and insulin comparator studies
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · week 40/42As given in this study (human).
Source sentences
Summary
Results were similar across pooled placebo, active, and insulin comparator studies.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615704
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, UACR lowering with tirzepatide appeared more pronounced in subgroups with baseline UACR of 30 mg/g or higher.
In plain wordsIn adults with type 2 diabetes, tirzepatide seemed to lower the urine kidney marker more in people who started with higher levels.
Peptide
Tirzepatide
Outcome
DecreaseUACR reduction in subgroups with baseline UACR 30 mg/g or higher
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · week 40/42As given in this study (human).
Source sentences
Summary
UACR lowering appeared more pronounced in subgroups with UACR ≥30 mg/g.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615705
06HumanRandomized controlled trialMechanism
In adults with type 2 diabetes, mediation analysis suggested that about one-half of the albuminuria reduction with tirzepatide may be weight loss related.
In plain wordsIn adults with type 2 diabetes, about half of the drop in the urine kidney marker with tirzepatide may be linked to weight loss.
Peptide
Tirzepatide
Outcome
Not applicableShare of albuminuria reduction related to weight loss (mediation)
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · week 40/42As given in this study (human).
Source sentences
Summary
Mediation analysis findings suggested that approximately one-half of the reduction in albuminuria associated with tirzepatide may be weight loss related.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615706
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, there was no difference in eGFR between tirzepatide and pooled comparators at week 40/42.
In plain wordsIn adults with type 2 diabetes, kidney filtration rate did not differ between tirzepatide and the pooled comparison treatments.
Peptide
Tirzepatide
Outcome
No significant changeeGFR difference versus pooled comparators at week 40/42
Study
n: not reported in source
Comparator
All pooled comparators
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · week 40/42As given in this study (human).
Source sentences
Summary
There was no difference in eGFR between tirzepatide and pooled comparators at week 40/42.
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis examined data from the overall pooled SURPASS-1-5 population and subgroups defined by baseline UACR ≥30 mg/g.
Report a problemFND-3974615707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.